within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX11_Quizartinib;

model Quizartinib_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.89,
    Cl = 1.6666666666666667e-06,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.11,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0033333333333333335,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Quizartinib_1</td></tr><tr><td>ATC code:</td><td>L01EX11_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>110</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Quizartinib is an oral, selective type II FLT3 inhibitor used in the treatment of acute myeloid leukemia (AML) with FLT3-ITD mutations. It is approved for use in adult patients and has demonstrated efficacy in relapsed or refractory AML.</p><h4>Pharmacokinetics</h4><p>Single-dose administration to healthy volunteers; parameters from noncompartmental analysis.</p><h4>References</h4><ol><li><p>Kang, D, et al., &amp; Yin, O (2020). Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of clinical pharmacology</i> 60(12) 1629–1641. DOI:<a href=\"https://doi.org/10.1002/jcph.1680\">10.1002/jcph.1680</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32598495/\">https://pubmed.ncbi.nlm.nih.gov/32598495</a></p></li><li><p>Usuki, K, et al., &amp; Sakajiri, S (2019). Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. <i>International journal of hematology</i> 110(6) 654–664. DOI:<a href=\"https://doi.org/10.1007/s12185-019-02709-8\">10.1007/s12185-019-02709-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31359361/\">https://pubmed.ncbi.nlm.nih.gov/31359361</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EX11_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Quizartinib_1;
